Novartis Claims Edge In CAR-T; Says Suicide Switch Still A Dream

Novartis AG believes the latest data for its chimeric antigen receptor T cell (CAR-T) therapy CTL019, presented at the American Society of Hematology (ASH) annual meeting, show it still has an edge over other CAR-T developers.